Codiak BioSciences to Pursue Asset Sale through Voluntary Chapter 11 Process
27 mars 2023 07h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx Conference
28 nov. 2022 13h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
10 nov. 2022 09h00 HE
|
Codiak BioSciences, Inc.
– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting...
Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress
03 nov. 2022 16h01 HE
|
Codiak BioSciences, Inc.
– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated during 1H 2023 – – Presented preclinical...
Codiak Presents Preclinical Data Demonstrating its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants of SARS-CoV-2 and Related Sarbecoviruses
12 oct. 2022 08h00 HE
|
Codiak BioSciences, Inc.
– Data support advancement of Codiak’s engineered exosome bivalent vaccine candidate toward IND-enabling studies – CAMBRIDGE, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc....
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
05 oct. 2022 08h00 HE
|
Codiak BioSciences, Inc.
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting – CAMBRIDGE, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...
Codiak Announces Pricing of $20 Million Public Offering of Common Stock and Warrants
12 sept. 2022 21h05 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company pioneering the development of exosome-based...
Codiak Announces Proposed Public Offering of Common Stock and Warrants
12 sept. 2022 16h01 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company pioneering the development of exosome-based...
Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring
30 août 2022 09h10 HE
|
Codiak BioSciences, Inc.
– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma – – Prioritizing vaccine program funded by CEPI...
Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress
04 août 2022 16h01 HE
|
Codiak BioSciences, Inc.
– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023 – – Initiated patient dosing in Phase 1...